Merck announced today that the phase 3 trial evaluating Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine and platinum-based chemotherapy has met its dual primary endpoint of overall survival (OS) as first-line treatment for patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma.

The results will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.

'Patients diagnosed with advanced gastric cancer often face a poor prognosis, underscoring the need for treatment options that can prolong patients' lives,' said Dr Marjorie Green, Senior Vice President at Merck Research Laboratories.

''These results are encouraging and build on the positive progression-free survival, overall response rate and duration of response data from this study,'' she added.

Copyright (c) 2024 All rights reserved.